NHS Artificial Pancreas Rollout Narrows Inequality in Diabetes Care
In England and Wales, the rollout of the artificial pancreas through the NHS for people with type 1 diabetes is showing modest but real progress in closing long-standing inequalities in access. According to figures reviewed by the Guardian, patients from deprived and minority ethnic backgrounds now access the device at rates notably more equal than they did with previous diabetes technologies.
Officially called a hybrid closed-loop system, the artificial pancreas consists of three connected parts: a sensor worn on the body that measures glucose levels continuously (a CGM); an algorithm running either on the pump or a separate device such as a phone, which calculates the precise insulin dose required; and an insulin pump that delivers that dose into the bloodstream. The system regulates blood sugar automatically through the night without requiring user input.
In 2024 the NHS announced a national commitment to offer the system to all type 1 diabetes patients within five years. To date, around 35,000 people have been fitted, about one-fifth of the eligible population. The thesis of the Guardian's report is that the rollout itself has narrowed the equality gap.
In Scotland, Wales and northern English regions, earlier-generation insulin pumps and continuous glucose monitors reached predominantly middle-class white British patients. In the early years of CGM uptake, patients of Asian background were 45% less likely to receive a pump than white British counterparts. With the artificial pancreas, that gap has narrowed to 19%.
According to NHS England, three factors account for the narrowing. First, because the artificial pancreas is funded by a national programme rather than hospital budgets, there is no cost barrier in the doctor-patient conversation. Second, education materials are now available in eleven languages for patients of Bangladeshi, Pakistani and Indian backgrounds. Third, the clinical specialist nurses who manage most referrals have been expanded by roughly 200 posts.
Dr Parijat De, who runs a diabetes clinic in Birmingham, told the Guardian: "What we explain to patients is that this is not insurance, not private. The system is already yours. That sentence has landed more in recent years — particularly the device scepticism from the previous generation of the family has been weakening."
The clinical benefit is also substantial. Patients on the artificial pancreas saw their average HbA1c (a measure of three-month blood sugar control) drop by 14 mmol/mol within six months. That is a clinically significant figure that correlates with major reductions in complications such as eye, kidney and nerve damage. Hypoglycaemia episodes were reported to have fallen by 60%.
Equal access is still not complete. The cost of the system through independent providers is around £8,000; the NHS pays roughly £1,300 a year per patient. Health Foundation data shows that patients who use private insurance or are treated outside the NHS still face long waiting times.
Access for children is another area where the gap persists. The system's lower age limit is seven. In the past six months, the NHS has opened access to about 1,200 children aged 4-7 through its Paediatric Diabetes Network. But the number of paediatric specialists has not expanded at the same rate as adult clinicians; waiting times are particularly long in Birmingham, Bradford and Glasgow.
The long-term monitoring plan will publish data every six months until 2030 to assess whether the rollout produces lasting equality gains rather than a one-off effect. "We have moved from the rhetoric of equal access to the data of equal access," said Professor Partha Kar, the NHS England national specialty adviser for diabetes. "That will be the real measure of success for this five-year programme."